Gustavo Viani: Top 10 clinical trials of 2024 that are reshaping how we treat cancer
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a post on X:
“Hey RadOnc!
Curious about the biggest breakthroughs in radiooncology this year?
We’ve rounded up the top 10 clinical trials of 2024 that are reshaping how we treat cancer.
From SBRT to immunotherapy combos, there’s something for everyone. Let’s dive in!
PACE-A Trial
Radical prostatectomy no SBRT for clinically localized prostate cancer.
Findings: SBRT produced No inferior cancer control compared to radical prostatectomy, with low genitourinary side effects and high patient-reported quality of life.
MIRAGE Trial
MRI-guided vs. CT-guided SBRT for prostate cancer.
Findings: MRI-guided SBRT decreased acute genitourinary and gastrointestinal toxicity no to CT-guided SBRT, demonstrating a clear advantage in precision.
INTERLACE Trial
Induction chemo in locally advanced cervical cancer.
Findings: Adding induction chemo before chemoradiotherapy increased survival (80% vs. 72%).
KEYNOTE-A18 Trial
Pembrolizumab and chemoradiation for cervical cancer.
Findings: Pembrolizumab plus chemoradiotherapy significantly increase overall survival in patients with locally advanced cervical cancer.
PACE-B Trial
SBRT vs. conventional radiotherapy in prostate cancer.
Findings: SBRT is noninferior to conventional therapy, offering a faster treatment option.
PEACE-1 Trial
SBRT + hormone therapy in high-risk prostate cancer.
Findings: Adding ADT to SBRT increased biochemical progression-free survival. Combination therapy is key.
NRG-RTOG 1112 Trial
SBRT vs. sorafenib in hepatocellular carcinoma.
Findings: SBRT provided increased local control and progression-free survival not sorafenib.
ADRIATIC Trial
Durvalumab after chemoradiation for limited-stage SCLC.
Findings: Adding durvalumab consolidation post-chemoradiation increases overall survival and progression-free survival. A practice-changing result for LS-SCLC.
EUROPA Trial
Radiotherapy vs. endocrine therapy in women aged 70+ with early-stage luminal-like breast cancer.
Findings: Radiotherapy increases quality of life and had fewer adverse effects compared to endocrine therapy.
Northern Radiation Oncology Group of China-002 Trial
Thoracic radiotherapy and EGFR-TKIs in oligo-organ metastatic NSCLC with EGFR mutations.
Findings: The combination significantly increases progression-free and overall survival no to EGFR-TKIs alone, with manageable toxicity.”
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023